About Type 1 phosphatidylinositol 4,5-bisphosphate 4-phosphatase
Type 1 phosphatidylinositol 4,5-bisphosphate 4-phosphatase (PIP4P1) is a protein
from Homo sapiens identified by UniProt accession
Q86T03, 277 residues long.
MolForge cross-references it against 0 known binders and
17 disease associations.
Target properties
| Protein name | Type 1 phosphatidylinositol 4,5-bisphosphate 4-phosphatase |
| UniProt accession | Q86T03 |
| Gene | PIP4P1 |
| Organism | Homo sapiens |
| Length | 277 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (17)
Diseases linked to this target (Open Targets).
- age at menopause · score 0.09
- blood protein measurement · score 0.06
- attention deficit hyperactivity disorder · score 0.06
- Tourette syndrome · score 0.05
- attention deficit-hyperactivity disorder 8 · score 0.05
- schizophrenia 15 · score 0.05
- Phelan-McDermid syndrome · score 0.04
- Potocki-Lupski syndrome · score 0.03
- X-linked non-syndromic intellectual disability · score 0.03
- X-linked dominant intellectual disability - epilepsy syndrome · score 0.03
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q86T03-F1 | alphafold | PREDICTED | 69.40 | — |
Amino-acid sequence (277 residues)
MAADGERSPL LSEPIDGGAG GNGLVGPGGS GAGPGGGLTP SAPPYGAAFP PFPEGHPAVL PGEDPPPYSP LTSPDSGSAP MITCRVCQSL INVEGKMHQH VVKCGVCNEA TPIKNAPPGK KYVRCPCNCL LICKVTSQRI ACPRPYCKRI INLGPVHPGP LSPEPQPMGV RVICGHCKNT FLWTEFTDRT LARCPHCRKV SSIGRRYPRK RCICCFLLGL LLAVTATGLA FGTWKHARRY GGIYAAWAFV ILLAVLCLGR ALYWACMKVS HPVQNFS
Explore Type 1 phosphatidylinositol 4,5-bisphosphate 4-phosphatase with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets